A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

NCT04400188 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Fluzoparib
DRUG: temozolomide
BIOLOGICAL: SHR-1316

Sponsor

Jiangsu HengRui Medicine Co., Ltd.